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a  b  s  t  r  a  c  t
BACKGROUND:  Hepatoid  Carcinoma  of  the Ovary  (HCO)  is  a rare subtype  of  ovarian  cancers  where  malig-
nant cells undergo  hepatoid  metamorphic  changes  and  cytologically  resemble  hepatocytes.  There are
many case  reports  of HCO  in the  literature,  and  patients  with  these  tumors  are  almost  uniformly  treated
with  palliative  debulking  and  conventional  adjuvant  chemotherapy.  To  our  knowledge,  there  is  only  one
case  report  of HCO  complicated  by peritoneal  dissemination  that was  treated  with  cytoreductive  surgery
plus  hyperthermic  intraperitoneal  chemotherapy  (CRS  plus HIPEC),  followed  by  adjuvant  chemotherapy.
CASE  SUMMARY:  A 47-year-old  female  presented  with  vague  lower  abdominal  pain.  Work-up  included
imaging  studies  and  biopsies  for histopathology  which  conﬁrmed  the  diagnosis  of  hepatoid  ovar-
ian  carcinoma  with  synchronous  liver  metastasis  and  peritoneal  dissemination,  without  evidence  of
extraperitoneal  disease.  She  underwent  a cytoreductive  surgery  plus hyperthermic  intraperitoneal
chemotherapy  (CRS  plus  HIPEC)  with  curative  intent.  Complete  cytoreduction  was  achieved  (CC-0).  Post-
operatively,  the  patient  elected  to forgo  adjuvant  therapy.  She  continues  to be  closely  followed  through
clinical  and radiological  surveillance.  On  her  most  recent  follow-up  visit,  she  achieved  22  months  of
disease-free  survival.
CONCLUSION:  CRS  plus  HIPEC  can be  considered  as  a  promising  curative  approach  for  HCO with  peritoneal
dissemination  in absence  of extraperitoneal  disease.  Further  studies  are  warranted  to  determine  the  role
of adjuvant  chemotherapy  in this  relatively  rare  entity.
©  2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Case report
This case was prepared and reported in line with the CARE cri-
eria [1]. Our patient is a 47-year old female with no signiﬁcant
ast medical or surgical history, BMI  of 31 kg/m2, who  presented
nitially with vague lower abdominal pain, not associated with
ny gastrointestinal symptoms including nausea, vomiting, con-
tipation or diarrhea. Her clinical exam conﬁrmed the presence
f a lower abdominal mass on deep palpation. She underwent
omputed tomography imaging that showed an ill-deﬁned, hetero-
eneous, left lobe liver lesion measuring 4.2 × 4.7 cm,  with multiple
nhancing soft tissue masses in the lower abdomen and pelvis
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coalescing to a maximum diameter of 10 cm.  Magnetic resonance
imaging revealed peritoneal dissemination in the left and right
lower quadrants and in the hypogastric region. (Figs. 1 and 2). Lab-
oratory work demonstrated an alpha-veto protein (AFP) level of
6669 ng/mL and CA-125 level of 144 U/mL. Further work-up did
not demonstrate any pulmonary or extraperitoneal metastases.
Preoperative Peritoneal Carcinomatosis Index (PCI) was calculated
according to Sugarbaker’s criteria [2,3] and revealed a score of
11The decision was  made to proceed with CRS plus HIPEC. CRS,
including left partial hepatectomy, was completed with complete
cytoreduction (CC score = 0). HIPEC was  conducted using Cisplatin
45 mg/L infused throughout the peritoneum in a closed-abdomen
technique for 90 min  at 42◦. Her postoperative hospital stay was
only remarkable for a pelvic abscess that required drainage. She
was discharged in a good state on day 14. After extensive discus-
sion with the multidisciplinary treating team, the patient opted to
forgo any adjuvant chemotherapy following her discharge.
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. T2-weighed MRI  of the pelvis. Pelvic complex mass with bilateral adnexal
involvement and omental invasion (asterisk).
Fig. 2. T1-weighed MRI  of the abdomen. 4.2 × 4.7 cm liver metastasis in the anterior









ian carcinomas with peritoneal dissemination, such as germ cellig. 3. Ovarian parenchymal carcinoma with classic hepatoid morphology (aster-
sk); uniform, cuboidal cells with eosinophilic cytoplasm.
The pathology report conﬁrmed the presence of hepatoid polyg-
nal malignant cells in the ovarian stroma (Fig. 3) with multiple
rgan involvement. Malignant cells had strong expression of Hep
ar 1, glypican-3, and cytokeratin 7, 8, and 18, whereas cytoker-
tin 20 was not detected. Negative margins were achieved on the
epatectomy specimen, and there was no evidence of cirrhosis in
iver.PEN  ACCESS
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She underwent serial surveillance imaging every 6 months post-
operatively, and achieved 22-months disease-free survival without
evidence of intra- or extra-peritoneal recurrence. Her follow up
laboratory work showed normalization of AFP and CA-125, and
the patient was satisﬁed with the overall outcome of the proce-
dure The timeline of the patient’s diagnosis and treatment course
is demonstrated in Table 1.
2. Discussion
HCO is a rare malignancy that arises primarily in the ovary, ﬁrst
described in 1987 by Ishikura and Scully [4]. They reported ﬁve
cases of HCO, two  of whom had liver metastases including one
who had other abdominal dissemination, similar to our patient.
The determination of the tumor’s origin was largely based on clin-
ical manifestation and histopathological features of the specimen,
where the lack of squamous, cholangiocellular, or adenoﬁbroma-
tous differentiation would strongly suggest an ovarian origin with
hepatoid morphology.
The most prominent microscopic features of HCO are the well
demarcated, cuboidal tumor cells arranged in trabeculae or sheets,
with eosin staining cytoplasm and hyaline globules on periodic
Acid-Schiff. [5]
HCO tumors uniformly stain positive for AFP which is usually
found to be elevated in the serum as well [6]. It is critically impor-
tant to distinguish HCO from hepatoid yolk sac tumors (HYST) and
metastatic hepatocellular carcinoma (HCC). The former can be fairly
easily ruled out by the absence of Hep-Par 1, a well-characterized
positive marker for hepatocellular differentiation, abundant in hep-
atocytes and hepatoid tumors [7]. On the contrary, discrimination
between HCO and metastatic HCC can be extremely challenging,
especially in the case of synchronous hepatic and ovarian involve-
ment. The tumor’s origin can be judged according to clinical and
pathological facts as mentioned above. Moreover, inhibin positiv-
ity has been proposed as a marker to discern HCC-derived cells
[8].
Extrahepatic tumors with hepatoid morphology most com-
monly arise in the stomach [9,10], and less commonly in other
viscera. HCO is considered a rare entity with 33 cases documented
since Ishikura and Scully’s report [4,6,8,11–33], described in both
pre- and post-menopausal females between 35 and 78 years old.
The vast majority of patients are found to have advanced disease
(stage III/IV) at the time of diagnosis. HCO is particularly known to
be locally and regionally aggressive. Metastatic disease most com-
monly manifests as peritoneal seeding and intraabdominal visceral
metastasis and less frequently as distant hematogenous spread.
In addition to the current report, one case was managed surgi-
cally with CRS plus HIPEC using paclitaxel as an intraoperative
agent [26]. The patient achieved a complete cytoreduction (CC = 0),
and was further treated with adjuvant chemotherapy consisting
of paclitaxel and carboplatin. The documented disease-free sur-
vival was 28 months. In another case report sorafenib was  used
due to paclitaxel intolerance, however was  unsuccessful in halting
the disease progression [8].
Interestingly, our patient experienced a signiﬁcant recurrence-
free survival of 21 months documented by radiologic and laboratory
testing following the use of a different HIPEC agent and waiver
of adjuvant therapy. This observation raises the query of whether
such a long-term outcome in HCO is more contingent on com-
plete cytoreduction rather than adjuvant regimens in the absence
of extraperitoneal disease. This would be in contrast to other ovar-tumors, whose mainstay of treatment is the adjuvant or neoadju-
vant chemotherapy regardless of the completeness of debulking
and irrespective of the size of residual disease [34].
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Table  1
The timeline of diagnosis, treatment, and follow up of our patient.
August 22nd, 2014 Initial presentation with vague lower abdominal pain
August 29th, 2014 Abdominal ultrasound revealed a liver lesion and lower abdominal mass
September 5th, 2014 Abdominal CT revealed an ill-deﬁned left hepatic lobe mass with multiple enhancing soft tissue masses in lower abdomen and
pelvis coalescing at 10 cm
September 7th, 2014 Abdominal MRI  conﬁrmed the above ﬁndings and detected peritoneal carcinomatosis
September 12th, 2014 CT-guided biopsy of the pelvis mass was positive for malignancy and consistent with HCC/HCO
September 13th, 2014 Laboratory work showed elevated AFP and CA-125
October 10th, 2014 Patient consulted for CRS plus HIPEC
October 15th, 2014 Abdominal MRI  was repeated: no evidence of disease progression
October 20th, 2014 CRS plus HIPEC
October 22nd, 2014 Discharge from ICU
October 27th, 2014 Pelvic abscess requiring IR drainage
November 4th, 2014 Discharge from hospital
January 14th, 2015 Abdominal MRI  was negative for recurrence. AFP and CA-125 normalized.
April 13th, 2015 Abdominal MRI  was negative for recurrence. Tumor markers were normal.































[October 19th, 2015 Abdominal MRI  was negative for recurrence
April 14th, 2016 Abdominal MRI  was negative for recurrence
August 8th, 2016 Abdominal MRI  was negative for recurrence
In conclusion, HCO remains a rare diagnosis and all evidence
vailable in the literature is based on case reports and series. At
his time, there is no consensus regarding the optimal management
f HCO, given the lack of high-level evidence. Current manage-
ent relies on systemic chemotherapy or immunomodulation with
arious levels of success as reported above. The combination of sur-
ical debulking and systemic therapy has been proposed in one
ase report. Our current report conﬁrms that CRS plus HIPEC can
e applied as a promising, and possible curative, option for this
isease. What we propose as a learning point is that adjuvant ther-
py may  be waived safely in this patient population if complete
ytoreduction is achieved and in absence of extraperitoneal spread.
urther evidence is necessary to conﬁrm these ﬁndings.
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